Psilocybin
Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy
The article Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy was originally published on Microdose.
In big news for access to mental…
The article Breaking News: Alberta 1st Province to Regulate Psychedelic Therapy was originally published on Microdose.
In big news for access to mental health treatments, Alberta has become the first Canadian province to regulate the use of psychedelics for therapy treatment.
On Wednesday, the province announced amendments to the Mental Health Services Protection Act, including changes to rules around opioids prescriptions for people with addiction and the amendments to psychedelic use. The province plans to regulate the use of psychedelics, including psilocybin, psilocin, MDMA, LSD, mescaline, DMT, 5 methoxy DMT, and ketamine, to treat psychiatric disorders. The regulations for psychedelics will come into effect on Jan. 16, 2023.
“Some of the strongest supporters are among first responders and veterans who suffer from high rates of PTSD and other mental health conditions,” said Mike Ellis, associate minister of mental health and addictions. “As a former police officer myself, I want to ensure that if there are promising practices to make life better for people with these conditions that we are supporting them in a professional way.”
As reported by the CBC, Alberta health officials said they are laying out a regulatory groundwork in the province. Alberta’s new regulations would require medical directors to apply for a license before treating patients with psychedelics for mental health disorders. A psychiatrist would have to oversee any treatment, according to the regulations taking effect in January 2023. Health professionals could not charge money for the drugs, and a qualified professional must only give patients the drug at a medical facility – unless the person is in palliative care.
This is an important step forward in not only providing access to treatments for patients in need, but in de-stigmatizing and normalizing psychedelic medicine.
See the full press conference below.
mescaline psilocybin mdma lsd ketamine dmt psychedelic therapy ptsd-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics7 days ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product